Summary
Stryker Corporation (SYK) reported its first-quarter 2025 results, showcasing robust top-line growth driven by strategic acquisitions and organic expansion. Net sales increased by 11.9% year-over-year to $5.87 billion, with constant currency growth of 12.8%. This growth was propelled by a 13.4% increase in the MedSurg and Neurotechnology segment and a 9.7% rise in the Orthopaedics segment. The company's profitability faced pressure from increased selling, general, and administrative expenses, largely due to acquisition-related costs, including a significant charge for Inari employee stock awards. As a result, net earnings decreased by 17.0% to $654 million, and diluted EPS fell to $1.69 from $2.05 in the prior year. However, adjusted EBITDA margin showed a healthier trend, indicating underlying operational strength. Financially, Stryker bolstered its liquidity through significant debt issuances, raising $2.98 billion in long-term debt. The company ended the quarter with a strong cash position, though it was reduced by substantial investing activities, primarily the Inari acquisition. The strategic acquisition of Inari, a leader in minimally invasive products for venous thromboembolism, is expected to enhance Stryker's Vascular business and drive future growth.
Financial Highlights
50 data points| Revenue | $5.87B |
| Cost of Revenue | $2.12B |
| Gross Profit | $3.74B |
| R&D Expenses | $405.00M |
| SG&A Expenses | $2.30B |
| Operating Expenses | $2.91B |
| Operating Income | $837.00M |
| Net Income | $654.00M |
| EPS (Basic) | $1.71 |
| EPS (Diluted) | $1.69 |
| Shares Outstanding (Basic) | 381.70M |
| Shares Outstanding (Diluted) | 386.40M |
Key Highlights
- 1Net sales grew 11.9% to $5.87 billion, driven by 13.4% in MedSurg/Neurotechnology and 9.7% in Orthopaedics.
- 2Acquisition of Inari Medical for $4.75 billion significantly boosted the Vascular business and contributed to overall sales growth.
- 3Net earnings declined 17.0% to $654 million ($1.69/share) due to increased SG&A expenses, particularly acquisition-related costs.
- 4Selling, General, and Administrative (SG&A) expenses rose 25.2% primarily due to a $139 million charge for Inari employee stock awards and other integration costs.
- 5The company raised $2.98 billion in new long-term debt, enhancing its liquidity position.
- 6Stryker is divesting its US Spinal Implants business, completing the sale in April 2025.
- 7Operating income margin decreased to 14.3% from 18.5% in the prior year, impacted by higher operating expenses.